🇺🇸 FDA
Pipeline program

Cisplatin Hikma 1 mg/ml Konzentrat zur Herstellung einer Infusionslösung, BAY 2927088 Bayer (CM), Pemetrexed Fresenius Kabi 25 mg/ml concentrate for solution for infusion, KEYTRUDA 25 mg/mL concentrate for solution for infusion, BAY 2927088, BAY 2927088 Bayer (CM), Carboplatin Kabi 10 mg/ml Konzentrat zur Herstellung einer Infusionslösung, BAY 2927088 Bayer

22615

Phase 3 small_molecule active

Quick answer

Cisplatin Hikma 1 mg/ml Konzentrat zur Herstellung einer Infusionslösung, BAY 2927088 Bayer (CM), Pemetrexed Fresenius Kabi 25 mg/ml concentrate for solution for infusion, KEYTRUDA 25 mg/mL concentrate for solution for infusion, BAY 2927088, BAY 2927088 Bayer (CM), Carboplatin Kabi 10 mg/ml Konzentrat zur Herstellung einer Infusionslösung, BAY 2927088 Bayer for Advanced non-small cell lung cancer with HER2 (ERBB2) mutation is a Phase 3 program (small_molecule) at Bayer AG with 1 ClinicalTrials.gov record(s).

Program details

Company
Bayer AG
Indication
Advanced non-small cell lung cancer with HER2 (ERBB2) mutation
Phase
Phase 3
Modality
small_molecule
Status
active

Clinical trials